Michael Shannon
Endocrinology, Diabetes & Metabolism · Lacey, WANPI 1366551285
Payments from drug & device makers
$698,092in general payments, 2019–2025
Across 831 payments — averaging $840.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$416K
- Bayer$159K
- Lilly USA, LLC$74K
- Boehringer Ingelheim$45K
- Eli Lilly$2K
- Shire North American Group Inc$1K
- plus $1K from 6 others
General payments by program year
19
20
21
22
23
24
25
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 411 | $415,575 |
| Bayer | 200 | $159,173 |
| Lilly USA, LLC | 143 | $74,346 |
| Boehringer Ingelheim | 63 | $44,703 |
| Eli Lilly | 2 | $2,027 |
| Shire North American Group Inc | 1 | $1,240 |
| AstraZeneca | 4 | $255 |
| Amgen | 2 | $233 |
| Genentech USA, Inc. | 1 | $150 |
| Corcept Therapeutics | 2 | $140 |
| Vifor Pharma, Inc. | 1 | $125 |
| AbbVie | 1 | $125 |
How this compares
$698,092 in reported general payments places this provider in the 95th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
See all endocrinology, diabetes & metabolism providers in Washington →
Other endocrinology, diabetes & metabolism in Lacey
- Ronald BrazgRenton$17.9M
- Frances BroylesSeattle$5.6M
- Leslie KlaffRenton$2.8M
- Carla GreenbaumSeattle$2.6M
- Irl HirschSeattle$2.4M
- William HagopianSeattle$2.1M
- Carol WyshamSpokane$1.6M
- Michael SchwartzSeattle$1.3M
- Lynn KohlmeierSpokane$518K
- Nicole EhrhardtSeattle$484K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.